83
Participants
Start Date
January 15, 2017
Primary Completion Date
April 28, 2023
Study Completion Date
July 15, 2023
Pembrolizumab
Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Hospital Virgen de la Luz, Cuenca
Hospital Lucus Agustí, Lugo
Fundación Jiménez Díaz, Madrid
Hospital Clínico San Carlos, Madrid
Hospital Universitario Sta Lucia, Cartagena
Hospital Dr. Peset, Valencia
Hospital La Fe, Valencia
Hospital Lluís Alcanyís, Xàtiva
Hospital Miguel Servet, Zaragoza
ICO-Hospitalet, L'Hospitalet de Llobregat
Consorci Sanitari de Terrassa, Terrassa
Hospital de la Santa Creu i Sant Pau, Barcelona
Spanish Lung Cancer Group
OTHER